세계의 항정신병약 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 용도별, 약제 분류별(제1세대, 제2세대), 지역별, 경쟁별(2020-2030년)
Antipsychotic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Drug Classification (First Generation, Second Generation ), By Region and Competition, 2020-2030F
세계의 항정신병약 시장은 2024년 152억 9,000만 달러로 평가되었고, 예측 기간 동안 CAGR 8.88%로 확대될 전망이며, 2030년에는 254억 8,000만 달러에 이를 것으로 예측됩니다.
이 시장은 조현병, 양극성 장애, 치료 저항성 우울증 등 심각한 정신 질환에 대응하는 의약품 분야의 중요한 구성 요소로서의 역할을 담당하고 있습니다. 항정신병약은 신경차단제로도 알려져 뇌 내 신경전달물질(주로 도파민)의 불균형을 표적으로 하여 환각, 망상, 기분 불안정 등의 증상을 관리 및 경감하도록 설계되어 있습니다. 사회적인 스트레스 요인과 라이프 스타일의 변화에 힘입어 정신 질환은 전 세계적으로 증가하고 있으며, 이러한 약물에 대한 수요는 점점 높아지고 있습니다. 세계보건기구(WHO)에 따르면 2019년에는 세계 거의 8명 중 1명이 정신장애를 앓고 있다고 합니다. 코로나19의 유행은 이 동향을 더욱 강하게 만들어 불안과 우울증 사례가 크게 증가했습니다. 인지도가 높아지고 편견이 사라지면서 치료를 찾는 사람들이 늘어나 시장 확대에 기여하고 있습니다. 항정신병약은 지속적으로 진화하여 유효성과 인용성을 개선하고 장기적인 정신과 의료와 이환 환자의 QOL 향상에 중요한 역할을 하고 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모(2024년) |
152억 9,000만 달러 |
| 시장 규모(2030년) |
254억 8,000만 달러 |
| CAGR(2025-2030년) |
8.88% |
| 급성장 부문 |
조현병 |
| 최대 시장 |
북미 |
시장 성장 촉진요인
정신질환 유병률 상승
주요 시장 과제
부작용
주요 시장 동향
맞춤형 의료 접근
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 항정신병약 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 용도별(조현병, 양극성 장애, 단극성 장애, 치매, 기타)
- 약제 분류별(제1세대(정형), 제2세대(비정형))
- 기업별(2024년)
- 지역별
- 시장 맵
제6장 북미의 항정신병약 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 북미 : 국가별 분석
제7장 유럽의 항정신병약 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 항정신병약 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 항정신병약 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 항정신병약 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 중동 및 아프리카 : 국가별 분석
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
제11장 시장 역학
제12장 시장 동향 및 발전
제13장 PESTEL 분석
제14장 Porter's Five Forces 분석
- 업계 내 경쟁
- 신규 진입의 가능성
- 공급자의 힘
- 고객의 힘
- 대체품의 위협
제15장 경쟁 구도
- Eli Lily and Company
- AstraZeneca plc
- GlaxoSmithKline plc
- Johnson & Johnson
- Otsuka Pharmaceutical Co, Ltd.
- Pfizer Inc.
- AbbVie Inc.
- Dr. Reddy's Laboratories Limited
- Otsuka Holdings Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
제16장 전략적 제안
제17장 기업 소개 및 면책사항
AJY
The Global Antipsychotic Drugs Market was valued at USD 15.29 billion in 2024 and is projected to reach USD 25.48 billion by 2030, expanding at a CAGR of 8.88% during the forecast period. This market serves as a vital component of the pharmaceutical sector, addressing serious mental health disorders such as schizophrenia, bipolar disorder, and treatment-resistant depression. Antipsychotic medications, also known as neuroleptics, are designed to manage and reduce symptoms like hallucinations, delusions, and mood instability by targeting neurotransmitter imbalances, primarily dopamine, in the brain. With mental health conditions on the rise globally, fueled by societal stressors and lifestyle changes, demand for these drugs is escalating. According to the World Health Organization, nearly one in eight people worldwide were living with a mental disorder in 2019. The COVID-19 pandemic further intensified this trend, with significant increases in cases of anxiety and depression. As awareness grows and stigmas diminish, more individuals are seeking treatment, contributing to market expansion. Antipsychotics continue to evolve, offering improved efficacy and tolerability, and playing a key role in long-term psychiatric care and quality-of-life improvement for affected patients.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 15.29 Billion |
| Market Size 2030 | USD 25.48 Billion |
| CAGR 2025-2030 | 8.88% |
| Fastest Growing Segment | Schizophrenia |
| Largest Market | North America |
Key Market Drivers
Rising Prevalence of Mental Health Disorders
The increasing global incidence of psychiatric conditions such as schizophrenia, bipolar disorder, and major depressive disorder is a primary growth driver for the antipsychotic drugs market. This rise is attributed to various factors including changing lifestyles, heightened stress levels, and improved diagnostic capabilities. Greater public awareness and reduced stigma around mental health are prompting more individuals to seek professional care. Consequently, this has led to higher diagnosis rates and an expanding patient population requiring pharmaceutical intervention. Antipsychotic drugs are essential in managing severe mental health symptoms, stabilizing patients, and preventing relapses. Their role in enhancing daily functioning and overall well-being has become increasingly prominent, aligning with the growing focus on holistic mental healthcare.
Key Market Challenges
Adverse Side Effects
A major challenge for the antipsychotic drugs market is the prevalence of adverse effects associated with these medications. Despite the advancements seen with second-generation (atypical) antipsychotics, many patients still experience side effects including significant weight gain, metabolic syndrome, sedation, and sexual dysfunction. These complications can hinder treatment adherence and diminish quality of life. Managing such side effects often requires additional medical oversight and therapeutic adjustments, which can increase healthcare costs and complicate patient care. This challenge underscores the importance of developing newer antipsychotic formulations with improved safety profiles to enhance patient compliance and long-term treatment outcomes.
Key Market Trends
Personalized Medicine Approach
The shift towards personalized medicine is a notable trend shaping the future of the antipsychotic drugs market. Leveraging pharmacogenomics, clinicians are now tailoring treatments to individual genetic profiles, enabling the selection of the most appropriate drug and dosage for each patient. This customized approach minimizes the risk of adverse effects and improves therapeutic efficacy. The integration of genetic testing and data-driven decision-making is helping to move beyond the traditional trial-and-error model, enhancing both clinical outcomes and patient satisfaction. As healthcare systems globally prioritize individualized care, personalized antipsychotic treatment strategies are expected to become a cornerstone in psychiatric therapy.
Key Market Players
- Eli Lily and Company
- AstraZeneca plc
- GlaxoSmithKline plc
- Johnson & Johnson
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer Inc.
- AbbVie Inc.
- Dr. Reddy's Laboratories Limited
- Otsuka Holdings Co., Ltd.
- Teva Pharmaceutical Industries Ltd
Report Scope:
In this report, the Global Antipsychotic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Antipsychotic Drugs Market, By Application:
- Schizophrenia
- Bipolar Disorder
- Unipolar Disorder
- Dementia
- Others
Antipsychotic Drugs Market, By Drug Classification:
- First Generation (Typical)
- Second Generation (Atypical)
Antipsychotic Drugs Market, By Region:
- North America
- United States
- Mexico
- Canada
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- India
- South Korea
- Japan
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Antipsychotic Drugs Market.
Available Customizations:
Global Antipsychotic Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Antipsychotic Drugs Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Application (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, Others)
- 5.2.2. By Drug Classification (First Generation (Typical), Second Generation (Atypical))
- 5.2.3. By Company (2024)
- 5.2.4. By Region
- 5.3. Market Map
6. North America Antipsychotic Drugs Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Application
- 6.2.2. By Drug Classification
- 6.2.3. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Antipsychotic Drugs Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Application
- 6.3.1.2.2. By Drug Classification
- 6.3.2. Mexico Antipsychotic Drugs Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Application
- 6.3.2.2.2. By Drug Classification
- 6.3.3. Canada Antipsychotic Drugs Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Application
- 6.3.3.2.2. By Drug Classification
7. Europe Antipsychotic Drugs Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Application
- 7.2.2. By Drug Classification
- 7.2.3. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Antipsychotic Drugs Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Application
- 7.3.1.2.2. By Drug Classification
- 7.3.2. Germany Antipsychotic Drugs Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Application
- 7.3.2.2.2. By Drug Classification
- 7.3.3. United Kingdom Antipsychotic Drugs Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Application
- 7.3.3.2.2. By Drug Classification
- 7.3.4. Italy Antipsychotic Drugs Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Application
- 7.3.4.2.2. By Drug Classification
- 7.3.5. Spain Antipsychotic Drugs Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Application
- 7.3.5.2.2. By Drug Classification
8. Asia-Pacific Antipsychotic Drugs Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Application
- 8.2.2. By Drug Classification
- 8.2.3. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Antipsychotic Drugs Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Application
- 8.3.1.2.2. By Drug Classification
- 8.3.2. India Antipsychotic Drugs Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Application
- 8.3.2.2.2. By Drug Classification
- 8.3.3. South Korea Antipsychotic Drugs Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Application
- 8.3.3.2.2. By Drug Classification
- 8.3.4. Japan Antipsychotic Drugs Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Application
- 8.3.4.2.2. By Drug Classification
- 8.3.5. Australia Antipsychotic Drugs Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Application
- 8.3.5.2.2. By Drug Classification
9. South America Antipsychotic Drugs Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Application
- 9.2.2. By Drug Classification
- 9.2.3. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Antipsychotic Drugs Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Application
- 9.3.1.2.2. By Drug Classification
- 9.3.2. Argentina Antipsychotic Drugs Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Application
- 9.3.2.2.2. By Drug Classification
- 9.3.3. Colombia Antipsychotic Drugs Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Application
- 9.3.3.2.2. By Drug Classification
10. Middle East and Africa Antipsychotic Drugs Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Application
- 10.2.2. By Drug Classification
- 10.2.3. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Antipsychotic Drugs Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Application
- 10.3.1.2.2. By Drug Classification
- 10.3.2. Saudi Arabia Antipsychotic Drugs Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Application
- 10.3.2.2.2. By Drug Classification
- 10.3.3. UAE Antipsychotic Drugs Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Application
- 10.3.3.2.2. By Drug Classification
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. PESTLE Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product
15. Competitive Landscape
- 15.1. Eli Lily and Company
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (As Reported)
- 15.1.5. Recent Developments
- 15.1.6. Key Personnel Details
- 15.1.7. SWOT Analysis
- 15.2. AstraZeneca plc
- 15.3. GlaxoSmithKline plc
- 15.4. Johnson & Johnson
- 15.5. Otsuka Pharmaceutical Co, Ltd.
- 15.6. Pfizer Inc.
- 15.7. AbbVie Inc.
- 15.8. Dr. Reddy's Laboratories Limited
- 15.9. Otsuka Holdings Co., Ltd.
- 15.10. Teva Pharmaceutical Industries Ltd.
16. Strategic Recommendation
17. About Us & Disclaimer
